Literature DB >> 27461138

Novel targets for paclitaxel nano formulations: Hopes and hypes in triple negative breast cancer.

Anita K Bakrania1, Bhavesh C Variya1, Snehal S Patel2.   

Abstract

Triple negative breast cancer is defined as one of the utmost prevailing breast cancers worldwide, possessing an inadequate prognosis and treatment option limited to chemotherapy and radiotherapy, creating a challenge for researchers as far as developing a specific targeted therapy is concerned. The past research era has shown several promising outcomes for TNBC such as nano-formulations of the chemotherapeutic agents already used for the management of the malignant tumor. Taking a glance at paclitaxel nano formulations, it has been proven beneficial in several researches in the past decade; nevertheless its solubility is often a challenge to scientists in achieving success. We have henceforth discussed the basic heterogeneity of triple negative breast cancer along with the current management options as well as a brief outlook on pros and cons of paclitaxel, known as the most widely used chemotherapeutic agent for the treatment of the disease. We further analyzed the need of nanotechnology pertaining to the problems encountered with the current paclitaxel formulations available discussing the strategic progress in various nano-formulations till date taking into account the basic research strategies required in terms of solubility, permeability, physicochemical properties, active and passive targeting. A thorough review in recent advances in active targeting for TNBC was carried out whereby the various ligands which are at present finding its way into TNBC research such as hyaluronic acid, folic acid, transferrin, etc. were discussed. These ligands have specific receptor affinity to TNBC tumor cells hence can be beneficial for novel drug targeting approaches. Conversely, there are currently several novel strategies in the research pipeline whose targeting ligands have not yet been studied. Therefore, we reviewed upon the numerous novel receptor targets along with the respective nano-formulation aspects which have not yet been fully researched upon and could be exemplified as outstanding target strategies for TNBC which is currently an urgent requirement.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Active targeting; Nanotechnology; Paclitaxel; Triple negative breast cancer

Mesh:

Substances:

Year:  2016        PMID: 27461138     DOI: 10.1016/j.phrs.2016.07.023

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  10 in total

1.  Fluoxetine induces autophagic cell death via eEF2K-AMPK-mTOR-ULK complex axis in triple negative breast cancer.

Authors:  Dejuan Sun; Lingjuan Zhu; Yuqian Zhao; Yingnan Jiang; Lixia Chen; Yang Yu; Liang Ouyang
Journal:  Cell Prolif       Date:  2017-11-01       Impact factor: 6.831

Review 2.  Silencing the roadblocks to effective triple-negative breast cancer treatments by siRNA nanoparticles.

Authors:  Jenny G Parvani; Mark W Jackson
Journal:  Endocr Relat Cancer       Date:  2017-02-01       Impact factor: 5.900

Review 3.  Exosome-Based Cancer Therapy: Implication for Targeting Cancer Stem Cells.

Authors:  Jinheng Wang; Yongjiang Zheng; Meng Zhao
Journal:  Front Pharmacol       Date:  2017-01-12       Impact factor: 5.810

4.  Role of β-Interferon Inducer (DEAE-Dextran) in Tumorigenesis by VEGF and NOTCH1 Inhibition along with Apoptosis Induction.

Authors:  Anita K Bakrania; Bhavesh C Variya; Snehal S Patel
Journal:  Front Pharmacol       Date:  2017-12-19       Impact factor: 5.810

5.  Dual drug-loaded nano-platform for targeted cancer therapy: toward clinical therapeutic efficacy of multifunctionality.

Authors:  Zhe Ma; Nan Li; Bing Zhang; YuYu Hui; Ying Zhang; Peng Lu; Jiaxin Pi; Zhidong Liu
Journal:  J Nanobiotechnology       Date:  2020-09-04       Impact factor: 10.435

Review 6.  The Role of Exosomes in Stemness and Neurodegenerative Diseases-Chemoresistant-Cancer Therapeutics and Phytochemicals.

Authors:  Narasimha M Beeraka; Shalini H Doreswamy; Surya P Sadhu; Asha Srinivasan; Rajeswara Rao Pragada; SubbaRao V Madhunapantula; Gjumrakch Aliev
Journal:  Int J Mol Sci       Date:  2020-09-17       Impact factor: 5.923

7.  Paclitaxel-based supramolecular hydrogel loaded with mifepristone for the inhibition of breast cancer metastasis.

Authors:  Cui-Cui Zhao; Chuan-Gui Zhang; Xuan Sun; Qingxiang Guo; Jinjian Liu; Yan Liu; Ya-Nan Hao; Guowei Feng; Lijun Yang; Hong Liu; Jianfeng Liu
Journal:  Cancer Sci       Date:  2021-12-18       Impact factor: 6.716

8.  Co-Delivery of 5-Fluorouracil and Paclitaxel in Mitochondria-Targeted KLA-Modified Liposomes to Improve Triple-Negative Breast Cancer Treatment.

Authors:  Tianyu Chen; Hui Chen; Yichun Jiang; Qi Yan; Shuling Zheng; Min Wu
Journal:  Pharmaceuticals (Basel)       Date:  2022-07-17

9.  Comparative colloidal stability, antitumor efficacy, and immunosuppressive effect of commercial paclitaxel nanoformulations.

Authors:  Jun Ye; Renjie Li; Yanfang Yang; Wujun Dong; Yujie Wang; Hongliang Wang; Tong Sun; Lin Li; Qiqi Shen; Caiyun Qin; Xiaoyan Xu; Hengfeng Liao; Yiqun Jin; Xuejun Xia; Yuling Liu
Journal:  J Nanobiotechnology       Date:  2021-07-05       Impact factor: 10.435

10.  Reduction of Circulating Cancer Cells and Metastases in Breast-Cancer Models by a Potent EphA2-Agonistic Peptide-Drug Conjugate.

Authors:  Ahmed F Salem; Si Wang; Sandrine Billet; Jie-Fu Chen; Parima Udompholkul; Luca Gambini; Carlo Baggio; Hsian-Rong Tseng; Edwin M Posadas; Neil A Bhowmick; Maurizio Pellecchia
Journal:  J Med Chem       Date:  2018-02-27       Impact factor: 7.446

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.